The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis

Gut and Liver

Volumn 6, Issue 2, 2012, Pages 256-261

  Yoo, Young Wook ^a   Cha, Sang Woo ^b   Kim, Anna ^c   Na, Seung Yeon ^c   Lee, Young Woo ^c   Kim, Sae Hee ^c   Lee, Hyang Ie ^c   Lee, Yun Jung ^c   Yang, Hyeon Woong ^c   Jung, Sung Hee ^c  

^a Cheongju St Mary's Hospital   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Eulji University   (South Korea)

Author keywords

Endoscopic retrograde cholangiopancreatography; Gabexate; Pancreatitis; Ulinastatin

Indexed keywords

GABEXATE MESILATE; SODIUM CHLORIDE; ULINASTATIN; ULISTIN; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ADULT; AMYLASE BLOOD LEVEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; HYPERAMYLASEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

EID: 84860329462     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2012.6.2.256     Document Type: Article

References (20)

1. Dumonceau JM, Andriulli A, Deviere J, et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: Prophylaxis of post-ERCP pancreatitis. Endoscopy 2010;42:503-515.
2. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy: Italian Group. N Engl J Med 1996;335:919-923. (Pubitemid 26314444)
3. Andriulli A, Solmi L, Loperfido S, et al. Prophylaxis of ERCPrelated pancreatitis: A randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004;2:713-718. (Pubitemid 39013432)
4. Tsujino T, Komatsu Y, Isayama H, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: A randomized, controlled trial. Clin Gastroenterol Hepatol 2005;3:376-383. (Pubitemid 40488346)
5. Yoo JW, Ryu JK, Lee SH, et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: A prospective, randomized, placebocontrolled trial. Pancreas 2008;37:366-370.
6. Choi CW, Kang DH, Kim GH, et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest Endosc 2009;69:e11-e18.
7. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: An attempt at consensus. Gastrointest Endosc 1991;37:383-393.
8. Manes G, Ardizzone S, Lombardi G, Uomo G, Pieramico O, Porro GB. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: A randomized, controlled, multicenter study. Gastrointest Endosc 2007;65:982-987. (Pubitemid 46783824)
9. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: A comprehensive review. Gastrointest Endosc 2004;59:845-864. (Pubitemid 38879313)
10. Testoni PA. Preventing post-ERCP pancreatitis: Where are we? JOP 2003;4:22-32. (Pubitemid 38963797)
11. Tsujino T, Kawabe T, Omata M. Antiproteases in preventing post-ERCP acute pancreatitis. JOP 2007;8(4 Suppl):509-517. (Pubitemid 47263693)
12. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002;56:488-495.
13. Ueki T, Otani K, Kawamoto K, et al. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A prospective, randomized trial. J Gastroenterol 2007;42:161-167. (Pubitemid 46404221)
14. Ohnishi H, Kosuzume H, Ashida Y, Kato K, Suzuki Y, Honjo I. Therapeutic effects of human urinary trypsin inhibitor on acute experimental pancreatitis. Nihon Yakurigaku Zasshi 1983;81:235-244. (Pubitemid 13124713)
15. Fujishiro H, Adachi K, Imaoka T, et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol 2006;21:1065-1069. (Pubitemid 43823296)
16. Chen S, Shi H, Zou X, Luo H. Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: The Emperor's New Clothes or Aladdin's Magic Lamp? Pancreas 2010;39:1231-1237.
17. Masci E, Cavallini G, Mariani A, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 2003;98:2182-2186. (Pubitemid 37305356)
18. Disario JA, Freeman ML, Bjorkman DJ, et al. Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology 2004;127:1291-1299. (Pubitemid 39457755)
19. Ueno N, Ozawa Y. Pancreatitis induced by endoscopic balloon sphincter dilation and changes in serum amylase levels after the procedure. Gastrointest Endosc 1999;49(4 Pt 1):472-476. (Pubitemid 29217335)
20. Sugiyama M, Izumisato Y, Abe N, Masaki T, Mori T, Atomi Y. Predictive factors for acute pancreatitis and hyperamylasemia after endoscopic papillary balloon dilation. Gastrointest Endosc 2003;57:531-535. (Pubitemid 36402720)